The Lancet Gastroenterology & Hepatology in conversation with

James Alexander on immune responses to COVID-19 vaccination in patients with IBD

The Lancet Gastroenterology & Hepatology

James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease.

Read the full article:
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP)

Continue this conversation on social!

Follow us today at...

https://bsky.app/profile/lancetgastrohep.bsky.social

https://www.linkedin.com/company/langastro/

https://instagram.com/thelancetgroup

https://facebook.com/thelancetmedicaljournal

https://youtube.com/thelancettv